Internal medicine - 4 News from the business & finance department by PhoreMost for the pharma industry

Tip: You can further refine your news selection by countries.

Internal medicine - 4 News from the business & finance department by PhoreMost for the pharma industry

Tip: You can further refine your news selection by countries.

image description

PhoreMost extends Series B financing to $50M to advance high-value oncology and inflammation degrader programmes

16-Sep-2024 - PhoreMost Ltd. announced it has added USD $12 million to its Series B financing, bringing the total raised to over $50 million. The additional investment was led by Parkwalk Advisors, the largest growth EIS fund manager, with participation from existing investors BGF, Dr Jonathan Milner, Amadeus ...

internal medicine oncology drug discovery
image description

PhoreMost enters multi-target collaboration with Arvinas

PhoreMost to deploy its SITESEEKER Targeted Protein Degradation platform to enable drug discovery against multiple therapeutic targets

03-Nov-2022 - PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, announced it has entered into a multi-target collaboration with Arvinas, an industry leader in targeted protein degradation (TPD). Under the terms of the agreement, PhoreMost will ...

internal medicine oncology active ingredient research
image description

PhoreMost and POLARISqb announce a multi-target collaboration to investigate next-generation cancer therapies

Start-ups combine biotechnology and artificial intelligence

06-Jan-2022 - PhoreMost Limited, a UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, and Polaris Quantum Biotech (POLARISqb), a NC-based quantum computing drug design company, announced a collaborationto study oncology targets currently considered ...

internal medicine oncology cancer therapy
image description

PhoreMost closes £33M Series B financing

Start-up is advancing its pipeline of novel therapies for oncology and diseases of ageing

25-Mar-2021 - PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, announced it has completed an oversubscribed £33m ($46m) Series B investment round. The round was led by BGF, the UK’s most active growth economy investor, and included new investors ...

internal medicine oncology ageing

These products might interest you

Askion FluoS®

Askion FluoS® by Askion

Automated Fluorescence Microscope - now incredibly affordable

Customizable. Affordable. Easy to use.

fluorescence microscopes
View product
Askion FluoM®

Askion FluoM® by Askion

Automated and customisable: fluorescence microscopy for diagnostics and research

Up to 4 fluorescence channels and 3 interchangeable objectives for maximum precision

fluorescence microscopes
View product
Naica Crystal Digital PCR System

Naica Crystal Digital PCR System by STILLA Technologies

High sensitivity and multiplexing for DNA/RNA detection and quantification-Naica Digital PCR System

Discover the potential of Crystal Digital PCR - a sensitive, fast and user-friendly solution

PCR systems
View product
Show all internal medicine
Haven't found the right news yet?

The bionity.com news search

Start your targeted search now with a wide range of filter options. Our database includes an archive of 27,240 life science news from business and science, which you can search by topic and organization, filtered by time and geography.

Start news search now